Non-invasive prostate cancer test may reduce biopsies

The French firm bioMérieux and ProteoSys, based in Mainz, Germany, have signed a license and development agreement for Annexin 3 to be used to develop a urine-based, confirmatory diagnostic test for prostate cancer.

After a research phase, the new test should be developed on the VIDAS platform.
Annexin 3, also known as ANXA 3, was discovered by ProteoSys, which specialises in cell biology and proteomics. Studies have shown that ANXA 3 quantification in urine is a novel, non-invasive test with high specificity for prostate cancer. Today, when the levels of prostate specific antigen (PSA) are in the uninformative ‘grey zone’, a biopsy is used to provide definitive diagnosis. The ANXA 3 test would be used to provide better identification of patients with a high probability of prostate cancer, thereby reducing the number of unnecessary biopsies.
After the first research phase at bioMérieux, a diagnostic test for the VIDAS platform will be developed. While the confirmatory diagnostic application on VIDAS will be the initial focus, bioMérieux is also considering the development of treatment decision and prognostic applications for ANXA 3.

28.10.2008

More on the subject:

Related articles

Photo

News • Environmental monitoring

New generation of smart sensors introduced

Manual calibration and parameter input in systems are time-intensive and error-prone, posing significant challenges across life sciences and hospitals. With a new generation of sensors, The Dickson…

Photo

News • Neurodegenerative disease

Alzheimer's: middle-age brain biomarkers give an earlier shot at prevention

The earlier Alzheimer's disease is detected, the more effective treatments become. Now, a Finnish study shows that signs related to Alzheimer’s may already be found in the brain in middle age.

Photo

Article • Medical Taiwan 2025: Company and product showcase

Transformative health solutions on display in Taipei

At Medical Taiwan 2025, manufacturers attracted attendees with a wide range of innovations. We took a closer look at some of the most exciting companies and their products on display at the medical,…

Related products

Subscribe to Newsletter